News

In accordance with the “Notice of the General Office of the Ministry of Ecology and Environment and the General Office of the National Development and Reform Commission on Deepening the Promotion of Clean Production Audits in Key Industries” (Huanban Kecai [2020] No. 27), the “Notice of the General Office of the People's Government of the Autonomous Region on Issuing the "Reform Action Plan of the Ningxia Hui Autonomous Region for Strengthening the Supervision, Utilization, and Disposal Capacity of Hazardous Waste" (Ningzhengban Guifa [2022] No. 9), and the “14th Five-Year Plan for the Prevention and Control of Environmental Pollution from Industrial Solid Waste in the Ningxia Hui Autonomous Region”, the Department of Ecology and Environment of the Ningxia Hui Autonomous Region issued the "Notice on Strengthening Mandatory Clean Production Audits for Hazardous Waste-Generating Entities in 2025" on June 17, 2025. This notice mandated that entities generating 100 tons or more of hazardous waste annually undergo mandatory clean production audits. Subsequently, on September 11, 2025, through the "Notice on Announcing the List of Key Enterprises for the Second Batch of Mandatory Clean Production Audits in 2025" (Ninghuanfa [2025] No. 74), Ningxia Qiyuan Pharmaceutical Co., Ltd. was designated as one of the key enterprises for the second batch of mandatory clean production audits in 2025. Consequently, the Company commenced the current round of clean production audit work in October 2025. I. Basic Profile of the Enterprise Ningxia Qiyuan Pharmaceutical Co., Ltd. was established through the restructuring and merger of the former Ningxia Pharmaceutical Factory and Ningxia Traditional Chinese Medicine Factory; it is a pharmaceutical enterprise with a history spanning over 60 years. Following its restructuring, the enterprise achieved rapid growth—bolstered by its acute market insight, robust R&D and production capabilities, as well as an advanced management model and a highly efficient management team—and has since emerged as one of the leading biopharmaceutical enterprises in China. The Company occupies a total area of ​​1,680 mu and employs nearly 1,000 staff members, ranking as one of the key industrial enterprises within the Autonomous Region. 1. Company Name: Ningxia Qiyuan Pharmaceutical Co., Ltd. 2. Legal Representative: Wu Yongming 3. Company Address: No. 1 Qiyuan Avenue, Wangyuan Industrial Park, Yinchuan City, Ningxia 4. Main Products and Production Scale: Tetracycline Hydrochloride (2,000 t/a); Vitamin C (20,000 t/a) 5. Primary Energy Consumption (2022–2024):6. Hazardous Waste Disposal Status:In accordance with the requirements of the "Law of the People's Republic of China on Promoting Clean Production" and the "Measures for Clean Production Auditing", we hereby publicly disclose the company's basic profile and its status regarding pollutant generation and discharge. We invite all sectors of society to oversee the company's implementation of its clean production audit.Contact Person: Yana FanMobile:+8615371019725WhatsApp/WeChat:+8615371019725E-mail:sales7@bouling-chem.com

In March 2023, Qiyuan Pharmaceutical was recognized as an "Outstanding Enterprise for Fulfilling Social Responsibility in 2022" and received a commendation from the Yinchuan Municipal Bureau of Industry and Information Technology. To thoroughly implement the “Implementation Opinions on Improving Corporate Governance Systems and Enhancing Governance Capabilities”—issued during the 10th Plenary Session of the 12th Autonomous Region Party Committee—various departments, including the Autonomous Region Department of Industry and Information Technology, the Development and Reform Commission, the Department of Human Resources and Social Security, the Department of Ecology and Environment, the Department of Emergency Management, the Department of Market Regulation, the Federation of Trade Unions, and the Tax Bureau, jointly issued a directive on May 20, 2022, to launch the 2022 evaluation of social responsibility fulfillment among industrial enterprises. Guided by Xi Jinping Thought on Socialism with Chinese Characteristics for a New Era, this evaluation targeted the Autonomous Region's industrial enterprises "above designated size" (as of the end of 2021) and state-level "Specialized, Refined, and New" "Little Giant" enterprises (31 entities). Adhering to the “Ningxia Guidelines for Evaluating Social Responsibility Fulfillment in Industrial Enterprises”, the assessment was structured around four major dimensions—"Economic," "Environmental," "Social," and "Corporate Governance"—which were further broken down into 25 second-tier indicators and 75 third-tier indicators. These served as the specific criteria for both corporate self-assessment and the scoring evaluations conducted by relevant government departments. The evaluation process was carried out through a comprehensive approach combining corporate self-assessment, departmental evaluation, and third-party review. The data collection period for the evaluation spanned from January 1 to December 31, 2021, with economic indicator data specifically based on the 2021 financial audit report. The evaluation workflow encompassed various stages, including data collection, guidance on report drafting, analysis and verification, and the compilation of the “Blue Book on Corporate Social Responsibility Fulfillment”. The application process for this initiative was characterized by a tight schedule and extensive content, necessitating the utmost accuracy in data and thoroughness in documentation. Administrative Director Xing Li attached great importance to this application project; the preliminary work was entirely organized by the Administrative Department, which—with the full cooperation of other relevant departments—successfully completed the submission, thereby demonstrating a highly professional and efficient work ethic. Qiyuan Pharmaceutical has consistently integrated the fulfillment of social responsibility into its core corporate values. The company remains steadfast in its commitment to optimizing its industrial structure, strengthening energy conservation and emission reduction efforts, and prioritizing environmental protection, while actively engaging in initiatives aimed at fostering a harmonious corporate environment. During the period of epidemic prevention and control, our company actively heeded the government's call. While rigorously maintaining our own internal preventive measures, we organized production in a robust and orderly manner, successfully fulfilling our mission to ensure product supply. By fully discharging our social responsibilities, we made significant contributions to epidemic control and socio-economic development within the Autonomous Region and Yinchuan City. Furthermore, we demonstrated our corporate mission and sense of duty to the public, earning widespread recognition and acclaim from all sectors of society. It is precisely because of our scientific and standardized management, our commitment to integrity and ethical business practices, our unwavering focus on product quality, our diligent safeguarding of employee rights, our conscientious fulfillment of corporate social responsibilities, and our active engagement in public welfare initiatives—striving to give back to society and exemplifying a spirit of public service—that we stood out among the 326 enterprises evaluated in our city. Consequently, we received a commendation from the Municipal Bureau of Industry and Information Technology and were honored with the top ranking. This award serves as a testament to the recognition bestowed upon Qiyuan Pharmaceutical by the government, society, and the general public; for Qiyuan Pharmaceutical, however, it marks a brand-new beginning. In the days ahead, guided by a profound sense of social responsibility and duty, Qiyuan Pharmaceutical will continue to push boundaries and raise the bar, striving to make new and even greater contributions to the advancement of public welfare initiatives and the construction of a harmonious society.

On December 12, 2022, Qiyuan Pharmaceutical was awarded the AEO Advanced Certified Enterprise Certificate by Yinchuan Customs. In early 2021, following preliminary consultations with Yinchuan Customs and an internal comparative assessment, Qiyuan Pharmaceutical decided to launch its AEO Advanced Certification project. This decision was made in strict accordance with the requirements of the "Measures of the Customs of the People's Republic of China for the Credit Management of Enterprises Registered or Recorded with the Customs" and the “Standards for Advanced Certified Enterprises”. Consequently, the company established a dedicated Customs Certification Team, led by the Marketing Department and comprising personnel from the Procurement, Administration, Microcomputer Management, Production Safety, and Finance Departments, as well as the Quality and Technology Center and Workshop 307. Working against the certification standards, the team conducted detailed inspections; revised and refined certification system documentation and records; rectified information system hardware and software; and comprehensively advanced all work related to the AEO Advanced Certification. On November 14, 2022, Qiyuan Pharmaceutical submitted its final application materials. A panel of Customs certification experts subsequently conducted a rigorous review of Qiyuan Pharmaceutical's internal controls, financial health, compliance standards, and trade security measures through on-site inspections, document reviews, and Q&A sessions. Ultimately, Qiyuan Pharmaceutical was approved for AEO Advanced Certification status. The Customs AEO Advanced Certification represents the highest credit rating for international trading enterprises—a status mutually recognized by customs authorities worldwide. It requires enterprises to demonstrate a robust management system, sound financial indicators, and comprehensive cargo security management protocols. By obtaining this certification, enterprises gain access to a range of customs facilitation measures—such as the lowest inspection rates, exemptions from guarantees, and priority customs clearance—thereby further reducing operational costs. The acquisition of this "Green Pass" for global trade undoubtedly injects new momentum into Qiyuan Pharmaceutical's continued efforts to deepen its presence in the international market.

Day-to-day life at an Active Pharmaceutical Ingredient (API) R&D and production base draws clear lines between talk and action. At Ningxia Qiyuan Pharmaceutical, our engineers and chemists work both shifts on autopilot and through the pressures that come with constant demand for new drug substances. Trends and global regulations push us to adapt quickly. Every time a new molecule progresses from the lab bench to the reactor, real people solve real challenges—temperature control, crystallization, purity levels, batch traceability. API manufacturing never stops evolving. That's because our customers require more than bulk chemical supply. Doctors and patients always look for consistency, and that puts responsibility squarely on our plant workers, formulation scientists, and regulatory teams.We see the need for reliable and reproducible synthesis. A single deviation in pressure, a minor mistake in timing, or an unnoticed impurity can send months of work back to start. Across thousands of reactors in our production base, we keep careful records, with electronic batch monitoring that sends alerts straight to our quality control center. For every new API, compliance standards get stricter. China's regulatory expectations now mirror or even exceed international benchmarks. Here, we meet not just China GMP standards, but also US FDA and EU requirements for many of our products. Our staff spends hours in continuing education, learning about ICH guidance, data integrity, the details of inspection frameworks. These steps do more than keep our facility certified. They reflect a deep commitment to patient safety—something that never feels abstract to anyone watching product batches ship out with their names listed as responsible.Chemistry responds to real-time needs of the market. In the last few years, several drugs lost patent protection. We have had to retool our pilot lines to launch new generic APIs quickly, but safely. Speed matters, but so does scalability. Sometimes a process that works in a lab glassware setup behaves very differently when transferred to thousand-liter reactors. Solubility, filtration, vacuum levels—plant operators face unpredictable hurdles. Our investment in high-level analytical equipment pays off when we spot problems before shipping. On the microbiological front, our team developed in-house rapid screening to catch bioburden issues early. Everyone on staff understands that losing a batch or issuing a recall brings significant financial hits and reputational risk. These pressures shape how we train, how we incentivize, and how we communicate on the shop floor.Environmental responsibility takes more than written promises. Many processes used to generate waste acid, heavy-metal-laden streams, or air emissions that could damage the surrounding community and ecosystem. At our base, we built multi-stage waste treatment and solvent recovery facilities. We devoted budget to upgrading emissions controls, retrofitted wastewater plants, and replaced old technologies with more sustainable ones. Regulators stepped up inspections, but we saw how early investment in green chemistry and full-lifecycle assessment could shield us from fines or shutdowns. Beyond regulatory obligation, most of our staff grew up in areas surrounding the plant. Any incident that affects air or water in this region impacts families of our workers. That gives these initiatives personal significance.We can’t ignore the global supply chain crunch. More multinational clients shifted from reliance on single suppliers after disruptions exposed by the pandemic. For us, that led to efforts in diversifying raw material sources and documenting every step of the supply chain. We conduct regular risk assessments together with suppliers, sending teams to audit not just factories but also the logistics pathways reaching Ningxia. Disruptions in precursors or reagents can delay shipment of critical APIs, and every missed day means lost opportunities for both partners and patients further down the line.People inside the plant tap their networks and hands-on knowledge to know what comes next. The push for innovation stays relentless. Our R&D team works closely with production engineers and maintenance crews, not just writing reports but actively troubleshooting problems as scale increases. Sometimes a change in raw materials triggers unwanted side reactions—someone in the lab or production catches it, digs into the chemistry, and suggests a tweak to temperature schedules or solvent ratios. Sometimes upstream process steps need redesign, turning to more selective catalysts or flow chemistry to improve yields and cut emissions. Success in API manufacturing comes from hundreds of these adjustments, not only from funding or machinery.Compliance, reliability, and innovation are inseparable. At Ningxia Qiyuan Pharmaceutical, we rely on our experience and constant adaptation to anticipate tough regulations, customer needs, and shifting markets. Safety, environmental stewardship, and product quality always run through every action at our base. Our stories rarely get told outside internal meetings, but each batch delivered stands as a testament to skill, accountability, and collective memory of what works and what needs fixing. Those routines and course corrections define our contribution to global health, more than anything found in marketing copy or annual reports.

Operating in Ningxia brings challenges and opportunities unique to China’s less-developed northwest. The arid landscape demands careful management of water resources and a real commitment to environmental regulations. Each new directive from government authorities requires on-the-ground adjustments — for instance, upgraded scrubbers and modernized wastewater treatment systems. This effort is not simply for compliance; it builds long-term viability. When the Yellow River’s water flow tightens in summer, every cubic meter matters to continued operations. As we increase efficiency, it isn't just cost-saving. Resource strain teaches us patience and new ways to balance production goals and environmental protection, especially with public pressure and peer scrutiny often higher for large industrial names.The push for skilled labor means more than posting vacancies online. Most technicians and plant operators in Ningxia are local, and developing their skills takes deliberate investment. Training programs go beyond onboarding — employees receive hands-on work with new process technologies and guidance from engineers familiar with both legacy equipment and modern upgrades. Trust builds through this knowledge transfer. Younger workers bringing digital skills and older staff with decades at the plant learn from each other, and that collaboration helps us adapt as stricter safety regulations and new standards appear almost every quarter. When the provincial government brings experts for chemical safety seminars or factory audits, our teams volunteer solutions and demonstrate what works on real factory floors, not just in paperwork.Domestic and international buyers both expect quality above cheap supply. Feedback arrives fast — sometimes in the form of transporter rejections, more often as technical claims from downstream users. Each shipment carries the weight of reputation, and quality control must keep up with every batch scaling. New partnerships with companies in Southeast Asia, the Middle East, and Eastern Europe mean specifications evolve fast, pushing us to tighten process controls and documentation. No shortcut replaces continued diligence in sampling, testing, and visually checking finished products alongside standard lab instruments. As new applications for base chemicals appear — agriculture, energy, water treatment — the need to share application experience and solve usage problems keeps the production and technical service teams close. Competitive advantage doesn’t come from speculation or undercutting: it’s the reliability of product and technical support that keeps clients returning even when spot prices fluctuate.Price rises for coal, energy, and other raw materials became sharper during global supply disruptions. Costs often climb suddenly, and our ability to offset those hikes depends on finding weaker points in production, collaborating with local suppliers, and contracting in advance. Transport remains a headache. Trains and trucks across northwest China face delays due to weather, roadwork, or regulatory checks. Advanced planning, quick communication with dispatch, and old-fashioned relationship-building with logistics partners matter just as much as digital tracking. Downstream customers rarely tolerate late shipments, and supply chain delays create real tension — not just lost profits, but risk to long-term trust built over years. Upgrades in warehouse management, closer ties with neighboring plants, and resource pooling sometimes help us survive the worst transport bottlenecks.Public concern about air and water emissions prompts stricter oversight. The era of “growth at any cost” has faded. Inspection teams visit frequently, sometimes unannounced, checking monitoring equipment, gathering effluent samples, and talking to staff at all levels. Fulfilling new environmental targets takes more than one-time upgrades; recurring assessment and process improvements are ongoing. In some years, government policy designates certain districts for temporary shutdowns during state inspections or heavy pollution alerts. This unpredictability requires contingency plans, including product stockpiling and flexible shift schedules so production can resume without major downtime. Real compliance happens shop-floor by shop-floor, enforced through both automated systems and operator vigilance. Stronger environmental record supports both social license and market access, especially as more buyers request proof of sustainability alongside traditional certifications.Innovation rarely arrives as grand breakthroughs; more often, it emerges through constant adjustment within strict regulatory, technical, and commercial boundaries. Process optimization often focuses on the details: minimizing waste in everyday operations, maximizing recycle streams, and lowering specific energy consumption step by step. Collaboration with local science and technology institutes sometimes brings new process catalysts, more efficient separation techniques, or digital monitoring systems to steady quality and reduce downtime. Tight budgets and conservative financial controls mean piloting smaller changes, slowly demonstrating value, and scaling successes without big fanfare. Steady technical progress, combined with deep local knowledge, sustains advantage in increasingly competitive markets.Standing as a chemical manufacturer in Ningxia means adapting to changing export requirements, foreign regulatory expectations, and shifting trade landscapes. Global demand can shift suddenly from Europe to Africa to Southeast Asia, each with its own documentation, safety requirements, and pricing volatility. Trade disputes and tariffs sometimes impact key products, requiring rapid pivots in product portfolio and negotiation tactics. Building long-term partnerships with global buyers, coupled with flexible capacity management, softens some of these shocks. Customer support teams need to resolve time zone barriers and language differences with direct, frequent communication, augmented with technical know-how rather than scripted responses. The best relationships thrive when technical staff and commercial managers visit customers, solving application problems jointly instead of transactional approach.Our experience in Ningxia’s chemical sector proves there is no substitute for direct problem-solving, shared knowledge in the workforce, and an honest approach to risk and reward. Modern manufacturing faces pressure from multiple fronts — energy transition, environmental standards, labor shortages, and competitive market shifts. Solutions come from within, through incremental changes, internal training, attention to real-world data, and strong relationships across supply chain and customer networks. The long-term future depends not on promises or slogans, but in the ability to deliver reliable quality, safe working conditions, honest cooperation with local communities, and real responsiveness to both market and public needs.

Ningxia Qiyuan Chinese Medicine Co., Ltd. is a wholly-owned subsidiary of Qiyuan Industrial Investment and a recognized high-tech enterprise, established in 2001. Integrating R&D, production, and sales, the company has received various regional designations, including "Enterprise Technology Center," "Ningxia Traditional Chinese Medicine Innovation Center," and "Specialized, Refined, and Innovative Demonstration Enterprise." The company possesses the manufacturing capabilities to produce both Western and Traditional Chinese medicinal preparations—encompassing five major dosage forms: tablets, granules, capsules, pills, and suppositories—as well as health foods and herbal extracts. Its core product portfolio includes the Jinlian Qingre series, Goji Berry series, Hawthorn Extract Lipid-Lowering series, and Vitamin C series. Upholding the corporate mission of "Building a Global Reputation, Promoting Health Across China" and the core values ​​of "Caring for Employees, Championing Innovation," the company has emerged as a key enterprise within Ningxia's pharmaceutical industry.

Ningxia Qiyuan Medicine Co., Ltd. is a wholly-owned subsidiary of Ningxia Qiyuan Industrial Co., Ltd., established in 2002. The company specializes in pharmaceutical distribution, wholesale, and retail chain operations. Its primary business scope encompasses proprietary Chinese medicines, raw Chinese medicinal materials, processed herbal pieces, chemical APIs and their preparations, antibiotics and their preparations, biochemical drugs, biological products, Class II psychotropic substances, anabolic agents and peptide hormones, and medical devices, among others. Within the Ningxia region, the company operates a network of directly managed retail pharmacies. The company maintains a comprehensive quality management system, features advanced facilities and equipment, and is equipped with a sophisticated information management system that enables end-to-end quality control across all stages of pharmaceutical procurement, storage, and sales.

Established in October 2014, Ningxia Yuyuan Biotechnology Co., Ltd. is a wholly-owned subsidiary of Ningxia Qiyuan Pharmaceutical Co., Ltd., with a registered capital of 20 million RMB. The company occupies a total land area of ​​483,333 square meters (approximately 725 mu) and features a built-up area of ​​8,000 square meters. As a high-tech enterprise grounded in biochemical manufacturing, Ningxia Yuyuan Biotechnology Co., Ltd. possesses mature technologies in the production of D-Sorbitol; it stands as the sole manufacturer of this product within the autonomous region, benefiting from significant geographical advantages and superior product quality control. The company's primary product portfolio consists of two categories: D-Sorbitol and hydrogen. Hydrogen is utilized in the manufacturing process of D-Sorbitol, while also serving as a key industrial raw material, industrial gas, and specialty gas.

Watching Ningxia Qiyuan Pharmaceutical grow over the years reminds me what steady commitment to quality actually means on the plant floor. In this business, the relevance of real production experience cannot be overstated. Claims about product character and batch-to-batch stability are not just marketing points; they’re about workers in shifts, raw material controls, and machinery humming during long nights. At Ningxia Qiyuan, that focus shows through the output, especially in active pharmaceutical ingredients and intermediates—these are not items slapped with a new label or sent through unknown hands, but true products of invested labor, process mapping, and unspoken pride among staff who keep the lines moving.Market demand pushes unpredictably, and only operators in the thick of production understand just how tight the tolerances really are. Regulatory authorities, especially in pharmaceuticals, don’t hand out approvals lightly and every change in process or supplier needs to be assessed, validated, documented, signed, and then tested again. One bad shipment or a missed test result can mean entire lots under lock and key. At Ningxia Qiyuan, quality management practices mean hands-on analysis, not just a paper trail for audits. Real-time decisions made by trained eyes running HPLC or GC, not just computers, prevent issues before products leave the door. This is how reliable pharmaceuticals are built at scale: from the ground up with chemistry lived every day.Many in the chemistry trade forget the importance of traceability, but in the plant, traceability means being able to walk from finished goods right back to the batch of acetone or acetic anhydride used four weeks back. It means having a production team that can explain process conditions at each stage, troubleshooting when something ends off-spec. At Ningxia Qiyuan, this discipline guides every step—whether it’s cephalosporin intermediates or antipyretic actives. Having QC labs on-site changes everything; retention samples kept in house allow us to answer questions not in months but in hours. This level of operational discipline isn’t an abstract promise; it’s the outcome of training, clean air management, raw material handling, and pressure to perform on schedule with heavy regulatory oversight.Compliance, for most manufacturers, is not a badge but a daily hurdle. Regulatory demands set by national agencies, central GMP standards, and customer audits all combine into an unending checklist. At Ningxia Qiyuan, workers don’t just follow protocols; they own them. Full-line documentation, electronic batch recording, cross-contamination barriers, and sterilization steps are built right into the way the line works. Such transparency satisfies foreign and domestic regulators, but also pays off on the customer side—clear records reinforce trust, and in pharmaceuticals, that trust forms the basis for real business partnership rather than short-term price shopping.Safety, too, stays at the center in a way outsiders rarely see. Manufacturing pharmaceuticals in Ningxia means addressing waste management, air quality, and personal exposure. Chemical residues, solvent vapors, heavy metals—these all find their way into our daily reality. Our staff wear PPE, follow clear lock-out procedures, and respond to near-misses before minor risks become lost-time incidents. These efforts lower batch rejection rates and raise morale, which reflects in the steadiness of annual output. Safe, steady production means fewer quality deviations, less rework, and a reputation built over decades rather than by quarterly sales numbers.It is never lost on the manufacturing team that Ningxia Qiyuan’s final products end up in medications that touch millions. These intermediates do not stop at the plant gate but make their way to compounding pharmacies and finished dosage manufacturers across many borders. Each kilo carries potential—and risk. Knowing every shipment is backed by analytical data, retained samples, and a track record with regulatory bodies means that hospitals and end-users are shielded from surprises. Staff see the direct consequence of even minor lapses—a spike in impurity here, a broken sterility protocol there. In this line of work, keeping the bar high is the only way to sleep at night.The company’s growth has brought new technologies into play—continuous process control systems, data logging for temperature and humidity, advances in crystallization units. But at its heart, the manufacturing expertise comes from hands that turn valves and eyes that watch reaction columns. R&D teams float new synthesis routes that take months to validate before the first commercial batch ever ships—this is the cost of doing things right, not just fast. Because in the end, what leaves the doors at Ningxia Qiyuan cannot be recalled with a simple apology; the burden of proof falls on the manufacturer, always.Competition forces manufacturers like us to push for operational efficiency and remain agile even as scrutiny grows tighter each year. Supply disruptions from pandemics or transport slowdowns have taught hard lessons about buffer stocks and key material contracts. As newer regulations emerge—whether for environmental controls, API impurity profiles, or data integrity—only those willing to adapt, invest, and document will survive. Ningxia Qiyuan’s production lines echo this reality: every improvement, from automation retrofits to staff continuing education, ties back into product reliability seen by customers and inspectors around the world.Looking back, it is the stubborn focus on quality, alone, that has set persistent chemical manufacturers apart from traders or intermediaries chasing the latest trend. Through the daily, unglamorous effort, companies like Ningxia Qiyuan continue to build the infrastructure that modern medicine depends on. Reliable supply, batch after batch, comes from sweat, investment, and a clear sense of responsibility for every flask, drum, and lot produced.